Drug Trial Radar · NCT04834427
Safety and Efficacy Evaluation of S (+) - Ketamine in Children
Last checked: Nov 19, 2026Latest source record: Mar 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
3,000
Planned (sponsor's estimate)
Start
Apr 20, 2022
Primary completion
Dec 1, 2024
Study completion Dec 4, 2024
Sponsor
- Lead sponsor
- Chinese PLA General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Southern Medical University, China; Beijing Children's Hospital; Shanghai Children's Medical Center; Hunan Children's Hospital
- First posted
- Apr 8, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter, randomized, open-label, active controlled pragmatic clinical trial that evaluates the safety and efficacy of S (+) -ketamine for postoperative acute pain in children in perioperative settings.
Conditions
- S-ketamine
- Esketamine
- Acute Pain
- Postoperative Pain
- Analgesia
- Hyperalgesia
- Delirium
- Depression, Anxiety
- Children
Interventions
Conventional therapy + S (+)-KetamineDrug
In principle, there are no specific restrictions on the dosage, mode of administration, timing, and compatibility of S-ketamine hydrochloride injection, but the recommended dosage is given, which is lower than the dosage specified in the instructions. Recommended use and dosage of S (+)-Ketamine: 1. Intravenous injection:Bolus intravenous injection before skin incision, the dose is 0.1\~0.25 mg/kg; Bolus intravenous injection (dose 0.1\~0.25 mg/kg) before skin incision + continuous intravenous infusion (dose of 0.1\~0.25 mg/kg/h) during operation; Continuous intravenous infusion after surgery with a dose of 0.02\~0.1 mg/kg/h for 24\~48 h. 2. Intramuscular injection:The dose is 2\~4 mg/kg.
Conventional therapyDrug
Receiving conventional therapy without S (+)-Ketamine hydrochloride injection. There is no restrictions in drugs, doses and incompatibility, the researchers can choose appropriate medication regimens based on clinical practice, but other NMDA receptor antagonists are not be allowed to use, such as dextromethorphan and amantadine.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The area under the broken line of FLACC scale scoreTime frame: Hour 0-48 after surgery
- The area under the broken line of Numerical Rating Scale scoreTime frame: Hour 0-48 after surgery
- Opioid consumptionTime frame: Hour 0-48 after surgery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.